| 產(chǎn)品編號(hào) | bs-15445R-HRP |
| 英文名稱(chēng)1 | Rabbit Anti-HECT E3 ubiquitin ligase/HRP Conjugated antibody |
| 中文名稱(chēng) | 辣根過(guò)氧化物酶標(biāo)記的HECT E3泛素鏈接酶抗體 |
| 別 名 | CEB1; CEBP1; Cyclin E binding protein 1; Cyclin-E-binding protein 1; E3 ISG15--protein ligase HERC5; HECT domain and RCC1 like domain containing protein 5; HECT domain and RCC1-like domain-containing protein 5; Hect domain and RLD 5; HECT E3 ubiquitin ligase; HERC5; HERC5_HUMAN; Herc6. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 染色質(zhì)和核信號(hào) 表觀(guān)遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Rat, (predicted: Human, ) |
| 產(chǎn)品應(yīng)用 | ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 117kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human HECT E3 ubiquitin ligase |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: HECT E3 ubiquitin ligase is a member of the HERC family of ubiquitin ligases and encodes a protein with a HECT domain and five RCC1 repeats. Pro-inflammatory cytokines upregulate expression of this gene in endothelial cells. The protein localizes to the cytoplasm and perinuclear region and functions as an interferon-induced E3 protein ligase that mediates ISGylation of protein targets. The gene lies in a cluster of HERC family genes on chromosome 4. Function: Major E3 ligase for ISG15 conjugation. Acts as a positive regulator of innate antiviral response in cells induced by interferon. Makes part of the ISGylation machinery that recognizes target proteins in a broad and relatively non-specific manner. Catalyzes ISGylation of IRF3 which results in sustained activation, it attenuates IRF3-PIN1 interaction, which antagonizes IRF3 ubiquitination and degradation, and boosts the antiviral response. Catalyzes ISGylation of influenza A viral NS1 which attenuates virulence; ISGylated NS1 fails to form homodimers and thus to interact with its RNA targets. Catalyzes ISGylation of papillomavirus type 16 L1 protein which results in dominant-negative effect on virus infectivity. Physically associated with polyribosomes, broadly modifies newly synthesized proteins in a cotranslational manner. In an interferon-stimulated cell, newly translated viral proteins are primary targets of ISG15. Subunit: Binds to CCNA1, CCNB1, CCND1 and CCNE1. Interacts with UBE2L6. Interacts with IRF3, this interaction is marginal in resting cells but enhanced upon viral infection. Subcellular Location: Cytoplasm, perinuclear region. Note=Associated with the polyribosomes, probably via the 60S subunit. Tissue Specificity: Expressed in testis and to a lesser degree in brain, ovary and placenta. Found in most tissues at low levels. Post-translational modifications: ISGylated (Probable). Similarity: Contains 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain. Contains 5 RCC1 repeats. Database links: Entrez Gene: 51191 Human Omim: 608242 Human SwissProt: Q9UII4 Human Unigene: 26663 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
